189 related articles for article (PubMed ID: 21935911)
1. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.
Lowry KP; Lee JM; Kong CY; McMahon PM; Gilmore ME; Cott Chubiz JE; Pisano ED; Gatsonis C; Ryan PD; Ozanne EM; Gazelle GS
Cancer; 2012 Apr; 118(8):2021-30. PubMed ID: 21935911
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
3. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
6. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
7. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
Phi XA; Saadatmand S; De Bock GH; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Hooning MJ; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; Tilanus-Linthorst MM; van den Heuvel ER; Houssami N
Br J Cancer; 2016 Mar; 114(6):631-7. PubMed ID: 26908327
[TBL] [Abstract][Full Text] [Related]
8. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
9. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
Heijnsdijk EA; Warner E; Gilbert FJ; Tilanus-Linthorst MM; Evans G; Causer PA; Eeles RA; Kaas R; Draisma G; Ramsay EA; Warren RM; Hill KA; Hoogerbrugge N; Wasser MN; Bergers E; Oosterwijk JC; Hooning MJ; Rutgers EJ; Klijn JG; Plewes DB; Leach MO; de Koning HJ
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1458-68. PubMed ID: 22744338
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
[TBL] [Abstract][Full Text] [Related]
11. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
[TBL] [Abstract][Full Text] [Related]
12. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in
Guindalini RSC; Zheng Y; Abe H; Whitaker K; Yoshimatsu TF; Walsh T; Schacht D; Kulkarni K; Sheth D; Verp MS; Bradbury AR; Churpek J; Obeid E; Mueller J; Khramtsova G; Liu F; Raoul A; Cao H; Romero IL; Hong S; Livingston R; Jaskowiak N; Wang X; Debiasi M; Pritchard CC; King MC; Karczmar G; Newstead GM; Huo D; Olopade OI
Clin Cancer Res; 2019 Mar; 25(6):1786-1794. PubMed ID: 30154229
[TBL] [Abstract][Full Text] [Related]
13. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.
Le-Petross HT; Whitman GJ; Atchley DP; Yuan Y; Gutierrez-Barrera A; Hortobagyi GN; Litton JK; Arun BK
Cancer; 2011 Sep; 117(17):3900-7. PubMed ID: 21365619
[TBL] [Abstract][Full Text] [Related]
15. The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations.
Hettipathirana T; Macdonald C; Xie J; Moodie K; Michael C; Phillips KA
Med J Aust; 2021 Nov; 215(10):460-464. PubMed ID: 34420218
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.
Phi XA; Houssami N; Obdeijn IM; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Tilanus-Linthorst MM; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; de Koning HJ; Van den Heuvel ER; de Bock GH
J Clin Oncol; 2015 Feb; 33(4):349-56. PubMed ID: 25534390
[TBL] [Abstract][Full Text] [Related]
17. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers.
Berrington de Gonzalez A; Berg CD; Visvanathan K; Robson M
J Natl Cancer Inst; 2009 Feb; 101(3):205-9. PubMed ID: 19176458
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
[TBL] [Abstract][Full Text] [Related]
19. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
